November 2018 | Volume 1

We focus on the industry's transition away from Poly-L-lactic acid-type resorbable polymers to updated and novel resorbable biomaterials designed for better clinical performance.
ROSA's first five cases were performed in a single surgery day by one surgeon. This perhaps hints that the company will position of ROSA as efficient and minimally disruptive to procedure flow. 

How will companies prioritize future R&D initiatives? We expect they'll balance development of smart implants, customization, materials, less-invasive surgery, tissue engineering and regrowth with requirements of data/evidence-based medicine and regulatory changes. 

Paradigm Spine specializes in motion preservation and non-fusion spinal devices. The cash and stock transaction, valued at US $300MM, is slated to close in 1Q19. 

More OEM M&A:  View all 2018 announcements

Investors at the Musculoskeletal New Ventures Conference pointed to extremities, sports medicine, digital health and hospital supply chain as areas attractive for innovation, funding and M&A.

This new algorithm -based software also tracks readmission rates and compares encrypted data to all other physicians who use the tool.

The registry will initially collect total shoulder arthroplasty procedures data. Rotator cuff repair and total elbow arthroplasty will follow in 2019. 

Manufacturers need not rely on go/no-go gaging methods. With non-contact video and multi-sensor systems, not only can 100% inspection be realized, but speed and throughput can increase. 
Our global industry requires companies to develop harmonized postmarket surveillance systems that minimize inconsistencies in our understanding of product lifecycle risks.